Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Shares Issued (2020 - 2025)

Exagen's Shares Issued history spans 6 years, with the latest figure at $398000.0 for Q4 2025.

  • For Q4 2025, Shares Issued rose 1909.09% year-over-year to $398000.0; the TTM value through Dec 2025 reached $22.6 million, changed N/A, while the annual FY2025 figure was $398000.0, N/A changed from the prior year.
  • Shares Issued reached $398000.0 in Q4 2025 per XGN's latest filing, down from $3.4 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $69.1 million in Q1 2021 to a low of -$69.1 million in Q3 2021.
  • Average Shares Issued over 5 years is $1.5 million, with a median of $126000.0 recorded in 2023.
  • The largest YoY upside for Shares Issued was 691340.0% in 2021 against a maximum downside of 48736.62% in 2021.
  • A 5-year view of Shares Issued shows it stood at -$48000.0 in 2021, then skyrocketed by 902.08% to $385000.0 in 2022, then crashed by 67.01% to $127000.0 in 2023, then tumbled by 117.32% to -$22000.0 in 2024, then skyrocketed by 1909.09% to $398000.0 in 2025.
  • Per Business Quant, the three most recent readings for XGN's Shares Issued are $398000.0 (Q4 2025), $3.4 million (Q3 2025), and $18.6 million (Q2 2025).